New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
06:18 EDTGSK, RBSRoyal Bank of Scotland's Hampton leads race to become new GSK chair, FT reports
Royal Bank of Scotland (RBS) Chairman Philip Hampton is the frontrunner to succeed Christopher Gent as chairman of GlaxoSmithKline (GSK), the Financial Times reports, citing sources. Gent will step down from his role at GSK next year. Hampton is not expected to step down from RBS until after May's general election, the sources say. Reference Link
News For GSK;RBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 5, 2015
15:02 EDTGSKNotable companies reporting before tomorrow's open
Subscribe for More Information
10:04 EDTRBSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:31 EDTGSKGlaxoSmithKline, partners make EU submission for gene therapy to treat ADA-SCID
Subscribe for More Information
05:32 EDTRBSRBS upgraded to Neutral from Reduce at Nomura
Subscribe for More Information
May 4, 2015
07:19 EDTRBSBanks in advanced talks with DOJ to settle forex rigging charges, Reuters says
JPMorgan (JPM), Citi (C), Royal Bank of Scotland (RBS), Barclays (BCS) and UBS (UBS) are in advanced talks with the Department of Justice on a collective settlement over charges of foreign exchange market rigging, said Reuters, citing people familiar with the matter. How the banks or their units will plead to charges is still in flux, though the collective settlement payment could exceed the $4.3B in fines paid by a half-dozen banks to regulators last November and a deal may be set by as soon as later this month, the report noted. Reference Link
May 3, 2015
18:11 EDTGSKSiemens investigated by Chinese regulator last year, Reuters says
Subscribe for More Information
May 1, 2015
07:43 EDTGSKExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 30, 2015
16:59 EDTGSKGlaxoSmithKline, Theravance announce FDA approval of Breo Ellipta
Subscribe for More Information
15:20 EDTGSKGlaxo says FDA issued CRL on use of Breo Ellipta in patients aged 12-17
Subscribe for More Information
15:17 EDTGSKGlaxoSmithKline says FDA approves BREO ELLIPTA for adults with asthma
GlaxoSmithKline (GSK) and Theravance (THRX) announced that the FDA has approved BREO ELLIPTA for the once-daily treatment of asthma in patients aged 18 years and older. Breo Ellipta is not indicated for the relief of acute bronchospasm. Breo is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25mcg and 200/25mcg, have been approved in the US for use in asthma, administered once-daily using the Ellipta dry powder inhaler.
07:21 EDTGSKFDA PDUFA Date for Theravance BREO ELLIPTA is April 30, 2015
06:25 EDTRBSEuro zone bank loans rose in March, NY Times says
Subscribe for More Information
05:57 EDTRBSRBS 'on track' to achieve 2015 targets
Subscribe for More Information
05:54 EDTRBSRBS reports Q1 profit GBP 325M vs. (GBP 375M) last year
Reports Q1 adjusted profit GBP 1.63B, up 16% from 2014. These results continued to benefit from generally benign credit conditions, with a GBP 91 million net release of impairment provisions, and from continuing reductions in operating costs. Reports Q1 attributable loss of GBP 446M, including restructuring costs of GBP 453M and GBP 856M of litigation and conduct charges. Tangible net asset value per ordinary and equivalent B share was 384p at 31 March 2015, compared with 387p at 31 December 2014. Reports Common Equity Tier 1 ratio of 11.5% at March 31, 2015.
April 27, 2015
10:04 EDTGSKHigh option volume stocks
Subscribe for More Information
08:46 EDTGSKAgenus data positive, says JMP Securities
Subscribe for More Information
08:41 EDTGSKTelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
06:19 EDTGSKPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
06:06 EDTRBSMizuho to buy North American loan portfolio from RBS, Telegraph reports
Royal Bank of Scotland (RBS) will sell a portfolio of North American loans to Mizuho Financial Group (MFG) for about $500M, The Telegraph reports. RBS will make a GBp20M loss on the deal, the report says. RBS says, "Together with the announced sale to Mizuho in late February, approximately two thirds of our North American corporate loan portfolio and associated commitments identified for exit have now been disposed of." Reference Link
April 24, 2015
07:11 EDTGSKAgenus: GSK's RTS,S vaccine showed statistically significant results in study
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use